You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PH1: Advanced Metrology and Sensors

    Release Date: 01-11-2022Open Date: 01-11-2022 Due Dates: Multiple Close Date: 10-26-2022

    PH1 SBIR/STTR Phase I (2022) National Science Foundation ...

    SBIR/STTRPhase INational Science Foundation
  2. PH2: Advanced Optical Components and Systems

    Release Date: 01-11-2022Open Date: 01-11-2022 Due Dates: Multiple Close Date: 10-26-2022

    PH2 SBIR/STTR Phase I (2022) National Science Foundation ...

    SBIR/STTRPhase INational Science Foundation
  3. PAS-22-197: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

    Release Date: 06-21-2022Open Date: 12-05-2022 Due Dates: Multiple Close Date: 09-05-2025

    Recommendations and milestones for Alzheimer's disease (AD) and AD-related dementias (ADRD) research from the National Alzheimer’s Project Act and, the 2015, 2018, 2019, and 2021 Alzheimer's Disease Research Summits present a wide range of research and development proposals which, if pursued, have the potential to reduce the human burden and healthcare costs associated with AD/ADRD. As part of ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PAS-22-196: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

    Release Date: 06-21-2022Open Date: 12-05-2022 Due Dates: Multiple Close Date: 09-08-2025

    Recommendations and milestones for Alzheimer's disease (AD) and AD-related dementias (ADRD) research from the National Alzheimer’s Project Act and the 2015, 2018, 2019, and 2021 Alzheimer's Disease Research Summits present a wide range of research and development proposals which, if pursued, have the potential to reduce the human burden and healthcare costs associated with AD/ADRD. As part of t ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAS-19-316 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

    Release Date: 07-18-2019Open Date: 12-05-2019 Due Dates: Multiple Close Date: 09-05-2022

    Recent recommendations and milestones for AD/ADRD research from the National Alzheimer’s Project Act, the 2015 Alzheimer’s Disease Research Summit, the 2018 Alzheimer’s Disease Research Summit, and the 2019 Alzheimer’s Disease and Related Dementias Research Summit present a wide range of research and development proposals which, if pursued, can reduce the human burden and healthcare costs ...

    SBIRPhase I/Phase IIDepartment of Health and Human Services
  6. PAS-19-317 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

    Release Date: 07-18-2019Open Date: 12-05-2019 Due Dates: Multiple Close Date: 09-05-2022

    Recent recommendations and milestones for AD/ADRD research from the National Alzheimer’s Project Act, the 2015 Alzheimer’s Disease Research Summit, the 2018 Alzheimer’s Disease Research Summit, and the 2019 Alzheimer’s Disease and Related Dementias Research Summit present a wide range of research and development proposals which, if pursued, can reduce the human burden and healthcare costs ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023

    Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Becaus ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-TR-22-029: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 07-13-2022Open Date: 07-18-2022 Due Dates: Multiple Close Date: 07-13-2023

    A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underlie multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molec ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-21-282: Blueprint Medtech: Small Business Translator (U44- Clinical Trial Optional)

    Release Date: 08-20-2021Open Date: 09-20-2021 Due Dates: Multiple Close Date: 06-21-2024

    Blueprint MedTech The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). Innovators developing groundbreaking medical ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-21-233: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 04-23-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government